A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer

Palliat Med. 2000 May;14(3):197-203. doi: 10.1191/026921600672294077.

Abstract

This was a prospective, randomized, open, crossover study comparing a mucin-based artificial saliva (Saliva Orthana) with a low-tack, sugar-free chewing gum (Freedent) in the management of xerostomia in patients with advanced cancer. The conclusions of this study were that both Saliva Orthana and Freedent are effective in the management of xerostomia in patients with advanced cancer, that both Saliva Orthana and Freedent cause some side-effects in this group of patients, and that patients with cancer think that chewing gum is an acceptable treatment. Sixty-nine per cent of the patients preferred the chewing gum to the artificial saliva. Furthermore, the chewing gum scored better than the artificial saliva on every measure of efficacy. However, none of these results reached statistical significance.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chewing Gum* / adverse effects
  • Chronic Disease
  • Cross-Over Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Palliative Care
  • Prospective Studies
  • Saliva / physiology*
  • Saliva, Artificial / therapeutic use*
  • Terminal Care
  • Treatment Outcome
  • Xerostomia / etiology
  • Xerostomia / therapy*

Substances

  • Chewing Gum
  • Saliva, Artificial